AI Stock Analysis - Praxis Precision Medicines Inc (PRAX)
Analysis generated October 16, 2025.
Praxis Precision Medicines Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, including rare and orphan diseases. The company's approach combines innovation in drug design with cutting-edge biological insights, aiming to address the needs of patients with debilitating neurological diseases.
Stock Alerts - Praxis Precision Medicines Inc (PRAX)
 |
Praxis Precision Medicines Inc | April 16 Price is down by -6.1% in the last 24h. |
|
Praxis Precision Medicines Inc | April 14 Price is up by 10.4% in the last 24h. |
|
Praxis Precision Medicines Inc | March 31 Price is up by 8.5% in the last 24h. |
|
Praxis Precision Medicines Inc | March 30 Price is down by -6.1% in the last 24h. |
Download our app on iOS or Android to get future alerts delivered in real-time.
Alternative Data for Praxis Precision Medicines Inc
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 32 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 16,000 | Sign up | Sign up | Sign up |
| Employee Rating | 52 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | 2,346 | Sign up | Sign up | Sign up |
| Instagram Followers | 447 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 14 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,713 | Sign up | Sign up | Sign up |
| X Followers | 664 | Sign up | Sign up | Sign up |
| X Mentions | 2 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 40 | Sign up | Sign up | Sign up |
| Linkedin Employees | 219 | Sign up | Sign up | Sign up |
About Praxis Precision Medicines Inc
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. The company is headquartered in Cambridge, Massachusetts.
| Price | $346.84 |
| Target Price | Sign up |
| Volume | 339,039 |
| Market Cap | $9.57B |
| Year Range | $37.71 - $347.55 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Praxis Precision Medicines, Inc. (PRAX) Q4 2025 Earnings Call TranscriptFebruary 19 - SeekingAlpha |
|
 |
Praxis Precision Medicines (NASDAQ:PRAX) Reports Q4 2025 Results Amid Key Regulatory MilestonesFebruary 18 - ChartMill |
 |
Needham Analyst Keeps a Buy Rating on Praxis Precision Medicines, Inc. (PRAX)January 10 - Yahoo Entertainment |
KCNQ2 Developmental and Epileptic Encephalopathy Market Research Report 2025-2035, Competitive Analysis of Biohaven, Xenon Pharma, Lundbeck, Praxis Precision Medicines, NeuShen TherapeuticsApril 28 - GlobeNewswire |
|
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential TremorApril 14 - GlobeNewswire |
|
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic EncephalopathyApril 6 - GlobeNewswire |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 0 | 66M | -66M | -74M | -74M | -3.360 |
| Q2 '25 | 0 | 63M | -63M | -71M | -76M | -3.310 |
| Q1 '25 | 0 | 61M | -61M | -69M | -75M | -3.290 |
| Q4 '24 | 7.5M | 56M | -49M | -59M | -64M | -2.940 |
| Q3 '24 | 300,000 | 0 | 300,000 | -52M | -57M | -2.750 |
Insider Transactions View All
| Nemiroff Alex filed to sell 29,932 shares at $193.2. November 21 '25 |
| Mastrocola Lauren filed to sell 10,442 shares at $192.7. November 21 '25 |
| Nemiroff Alex filed to sell 44,248 shares at $190.9. November 21 '25 |
| Nemiroff Alex filed to sell 20,832 shares at $194.3. November 21 '25 |
| Mastrocola Lauren filed to sell 12,587 shares at $192. November 21 '25 |
Similar companies
Read more about Praxis Precision Medicines Inc (PRAX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Praxis Precision Medicines Inc
The Market Cap of Praxis Precision Medicines Inc is $9.57B.
Currently, the price of one share of Praxis Precision Medicines Inc stock is $346.84.
The PRAX stock price chart above provides a comprehensive visual representation of Praxis Precision Medicines Inc's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Praxis Precision Medicines Inc shares. Our platform offers an up-to-date PRAX stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Praxis Precision Medicines Inc (PRAX) does not offer dividends to its shareholders. Investors interested in Praxis Precision Medicines Inc should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Praxis Precision Medicines Inc are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
